445 related articles for article (PubMed ID: 23415997)
1. Response to ovarian stimulation in patients facing gonadotoxic therapy.
Johnson LN; Dillon KE; Sammel MD; Efymow BL; Mainigi MA; Dokras A; Gracia CR
Reprod Biomed Online; 2013 Apr; 26(4):337-44. PubMed ID: 23415997
[TBL] [Abstract][Full Text] [Related]
2. Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes.
Turan V; Bedoschi G; Emirdar V; Moy F; Oktay K
Reprod Sci; 2018 Jan; 25(1):26-32. PubMed ID: 28874104
[TBL] [Abstract][Full Text] [Related]
3. The impact of letrozole administration on oocyte morphology in breast cancer patients undergoing fertility preservation.
Bercaire LMN; Cavagna M; Donadio NF; Rocha AR; Portela R; Alves VR; Santos TBB; Cavagna F; Dzik A; Gebrim LH; Nahas EAP
JBRA Assist Reprod; 2020 Jul; 24(3):257-264. PubMed ID: 32293820
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial.
Dahhan T; Balkenende EME; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; van Golde RJT; Schipper I; Louwé LA; Cantineau AEP; Smeenk JMJ; de Bruin JP; Reddy N; Kopeika Y; van der Veen F; van Wely M; Linn SC; Goddijn M
Contemp Clin Trials; 2017 Oct; 61():96-100. PubMed ID: 28710053
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†.
Pereira N; Hancock K; Cordeiro CN; Lekovich JP; Schattman GL; Rosenwaks Z
Gynecol Endocrinol; 2016 Oct; 32(10):823-826. PubMed ID: 27114051
[TBL] [Abstract][Full Text] [Related]
6. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Azim AA; Costantini-Ferrando M; Oktay K
J Clin Oncol; 2008 Jun; 26(16):2630-5. PubMed ID: 18509175
[TBL] [Abstract][Full Text] [Related]
7. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer?
Revelli A; Porcu E; Levi Setti PE; Delle Piane L; Merlo DF; Anserini P
Gynecol Endocrinol; 2013 Nov; 29(11):993-6. PubMed ID: 24000936
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of random-start controlled ovarian stimulation in cancer patients.
Kim JH; Kim SK; Lee HJ; Lee JR; Jee BC; Suh CS; Kim SH
J Korean Med Sci; 2015 Mar; 30(3):290-5. PubMed ID: 25729252
[TBL] [Abstract][Full Text] [Related]
9. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?
Drakopoulos P; Blockeel C; Stoop D; Camus M; de Vos M; Tournaye H; Polyzos NP
Hum Reprod; 2016 Feb; 31(2):370-6. PubMed ID: 26724797
[TBL] [Abstract][Full Text] [Related]
10. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
[TBL] [Abstract][Full Text] [Related]
11. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients.
Turan V; Bedoschi G; Moy F; Oktay K
Fertil Steril; 2013 Dec; 100(6):1681-5.e1. PubMed ID: 24055050
[TBL] [Abstract][Full Text] [Related]
12. Mild ovarian stimulation with letrozole plus fixed dose human menopausal gonadotropin prior to IVF/ICSI for infertile non-obese women with polycystic ovarian syndrome being pre-treated with metformin: a pilot study.
D'Amato G; Caringella AM; Stanziano A; Cantatore C; Palini S; Caroppo E
Reprod Biol Endocrinol; 2018 Sep; 16(1):89. PubMed ID: 30217209
[TBL] [Abstract][Full Text] [Related]
13. Random-start ovarian stimulation in patients with cancer.
Cakmak H; Rosen MP
Curr Opin Obstet Gynecol; 2015 Jun; 27(3):215-21. PubMed ID: 25919235
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of ovarian stimulation after treatment with chemotherapy.
Chan JL; Johnson LN; Efymow BL; Sammel MD; Gracia CR
J Assist Reprod Genet; 2015 Oct; 32(10):1537-45. PubMed ID: 26400507
[TBL] [Abstract][Full Text] [Related]
15. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy.
Abir R; Ben-Aharon I; Garor R; Yaniv I; Ash S; Stemmer SM; Ben-Haroush A; Freud E; Kravarusic D; Sapir O; Fisch B
Hum Reprod; 2016 Apr; 31(4):750-62. PubMed ID: 26848188
[TBL] [Abstract][Full Text] [Related]
16. Ovarian response to stimulation for fertility preservation in women with hematologic cancer.
Brun T; Dion L; Jaillard S; Bales D; Domin M; Lavoué V; Levêque J; Houot R; Duros S
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101925. PubMed ID: 33010467
[TBL] [Abstract][Full Text] [Related]
17. GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept study.
Olgan S; Humaidan P
Reprod Biol; 2017 Mar; 17(1):105-110. PubMed ID: 28173995
[TBL] [Abstract][Full Text] [Related]
18. Diminished ovarian reserve and poor response to stimulation in patients <38 years old: a quantitative but not qualitative reduction in performance.
Morin SJ; Patounakis G; Juneau CR; Neal SA; Scott RT; Seli E
Hum Reprod; 2018 Aug; 33(8):1489-1498. PubMed ID: 30010882
[TBL] [Abstract][Full Text] [Related]
19. Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial.
Letourneau J; Juarez-Hernandez F; Wald K; Ribeiro S; Wang A; McCulloch CE; Mok-Lin E; Dolezal M; Chien AJ; Cedars MI; Rosen M
J Assist Reprod Genet; 2021 Sep; 38(9):2455-2463. PubMed ID: 34312774
[TBL] [Abstract][Full Text] [Related]
20. Fertility preservation after gonadotoxic treatments for cancer and autoimmune diseases.
Saito S; Yamada M; Yano R; Takahashi K; Ebara A; Sakanaka H; Matsumoto M; Ishimaru T; Utsuno H; Matsuzawa Y; Ooka R; Fukuoka M; Akashi K; Kamijo S; Hamatani T; Tanaka M
J Ovarian Res; 2023 Aug; 16(1):159. PubMed ID: 37563616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
